Neurona Therapeutics Dosed Initial Subject in First Clinical Trial of Regenerative Human Cell Therapy

June 30, 2022
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today announced the first patient dosed in a Phase 1/2 clinical trial of its lead program, NRTX-1001, in a first-in-human epi

Erasca Announces Trial to Evaluate ERAS-007

June 23, 2022
“We look forward to ERAS-007 being evaluated in this trial, based in part on ERAS-007's ability in preclinical studies to robustly shut down oncogenic signaling,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. MORE

Aclarion Presents Two Year Results and the Schedule of Future Clinical Trials

June 23, 2022
Aclarion, Inc. a healthcare technology company founded on UCSF orthopedic surgeon Jeffery Lotz's research leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that the Company will be participating in the 17th Annual State of Spine...

Free Legal Services for Start-Ups

June 21, 2022
Do you know a startup that could use a free lawyer?

Innovation to Impact (I2I) at Yale

June 14, 2022
The application deadline for I2I, a fantastic, no-cost education, and enrichment opportunity, has been extended to June 30!  APPLY

Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application

June 10, 2022
Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S.

Prescription Video Game Treatment

May 27, 2022
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox. The Roblox vision for bringing people together through shared experiences, plus the Akili commitment to a new era of cognitive medicine, make the companies ideal partners to...

Aclarion Announces $9.4 Million Initial Public Offering

April 25, 2022
The healthcare technology company founded by UCSF researcher Jeffery Lotz, PhD, that leverages Magnetic Resonance Spectroscopy (“MRS”), artificial intelligence, and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced the pricing of its initial public...

Video Game Improves Cognitive Symptoms

April 14, 2022
Its first product, EndeavorRx was developed by Adam Gazzaley, Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, to help improve attention in children between the ages of 8 and 12 with attention deficit hyperactivity disorder, or ADHD. Following it...

Exai Bio shows Its Unique RNA-based Liquid Biopsy Strategy for Early Cancer Detection

April 12, 2022
Next-generation liquid biopsy company, Exai Bio, presented data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs (oncRNAs), and the validation of artificial intelligence (AI) profiling of oncRNAs to accurately detect cancers of diverse...